You just read:

Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (PedPRM) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD)

News provided by

Neurim Pharmaceuticals Ltd.

02 Nov, 2016, 09:00 ET